Hormone receptor–positive (HR+) breast cancer (BC) constitutes 70%–75% of breast tumors, characterized by the expression of the estrogen receptor α (ER+) and the progesterone receptor (PR+) (1, 2). This evidence concerns the gene NR4A1 and breast carcinoma.